Peptide Health Digest Logo
Therapeutic Category Hub

Hormonal Health

Selective secretagogues and releasing hormones researched for optimizing endocrine regulation safely.

Peptides in this Category (6)

Target compounds
Research CompoundModified GRF (1-29)
CJC-1295
A synthetic growth hormone-releasing hormone (GHRH) analog engineered with 4 amino acid substitutions to resist enzyme cleavage.
Biological Half-Life~30 minutes (no DAC) / 6-8 days (with DAC)
Research CompoundSelective GH Secretagogue
Ipamorelin
A selective pentapeptide ghrelin receptor agonist that stimulates growth hormone release with minimal impact on cortisol, prolactin, or aldosterone.
Biological Half-Life~2 hours
Research CompoundEpithalamin Tetrapeptide
Epithalon
A synthetic pineal-derived tetrapeptide researched for activating telomerase, restoring melatonin rhythms, and extending lifespan in somatic and cellular models.
Biological Half-Life~30 - 45 minutes (rapid intracellular genomic signaling)
FDA ApprovedMelanocortin Agonist
Bremelanotide (PT-141)
A cyclic heptapeptide melanocortin receptor agonist (MC3R/MC4R) FDA approved for hypoactive sexual desire disorder, acting directly within the central nervous system.
Biological Half-Life~2.7 hours
FDA ApprovedGHRH (1-29) Amide
Sermorelin
A 29-amino acid truncated analog of growth hormone-releasing hormone representing the shortest fully functional biological fragment capable of stimulating pituitary GH secretion.
Biological Half-Life~12 - 20 minutes
Clinical TrialsKP-10
Kisspeptin-10
An endogenous C-terminal decapeptide that acts as the primary neuroendocrine gatekeeper of gonadotropin-releasing hormone (GnRH) and reproductive axis signaling.
Biological Half-Life~4 - 10 minutes

Related Clinical Studies (3)

Browse All Studies →
In Vitro / Laboratory2003-06-15

Epithalon Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells

Foundational laboratory investigation demonstrating that the pineal tetrapeptide Epithalon overcomes somatic cellular senescence by reactivating telomerase expression and elongating telomeres.

Bulletin of Experimental Biology and MedicineRead Study
Human Clinical Research2019-11-01

Bremelanotide for Hypoactive Sexual Desire Disorder: Phase 3 RECONNECT Clinical Program

Pivotal phase 3 registration trials leading to FDA approval of bremelanotide, demonstrating central melanocortin receptor-mediated improvements in sexual desire and reduction in related distress.

Obstetrics & GynecologyRead Study
Human Clinical Research2011-09-01

Kisspeptin-10 Stimulates Hypothalamic Gonadotropin-Releasing Hormone and LH Pulsatility in Healthy Men

Clinical endocrine study establishing that intravenous kisspeptin-10 administration rapidly stimulates hypothalamic GnRH and pituitary LH secretion without downstream endocrine receptor exhaustion.

Journal of Clinical Endocrinology & Metabolism (JCEM)Read Study